DE69033109D1 - Rezeptoren für fibroblasten-wachstumsfaktoren - Google Patents

Rezeptoren für fibroblasten-wachstumsfaktoren

Info

Publication number
DE69033109D1
DE69033109D1 DE69033109T DE69033109T DE69033109D1 DE 69033109 D1 DE69033109 D1 DE 69033109D1 DE 69033109 T DE69033109 T DE 69033109T DE 69033109 T DE69033109 T DE 69033109T DE 69033109 D1 DE69033109 D1 DE 69033109D1
Authority
DE
Germany
Prior art keywords
growth factor
fibroblast growth
fgf
factor receptors
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69033109T
Other languages
English (en)
Other versions
DE69033109T2 (de
Inventor
Lewis Williams
Daniel Johnson
Pauline Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of DE69033109D1 publication Critical patent/DE69033109D1/de
Application granted granted Critical
Publication of DE69033109T2 publication Critical patent/DE69033109T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
DE69033109T 1989-07-06 1990-07-06 Rezeptoren für fibroblasten-wachstumsfaktoren Expired - Lifetime DE69033109T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37700389A 1989-07-06 1989-07-06
PCT/US1990/003830 WO1991000916A2 (en) 1989-07-06 1990-07-06 Receptors for fibroblast growth factors

Publications (2)

Publication Number Publication Date
DE69033109D1 true DE69033109D1 (de) 1999-06-17
DE69033109T2 DE69033109T2 (de) 1999-11-18

Family

ID=23487374

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69033109T Expired - Lifetime DE69033109T2 (de) 1989-07-06 1990-07-06 Rezeptoren für fibroblasten-wachstumsfaktoren

Country Status (15)

Country Link
US (4) US6384191B1 (de)
EP (1) EP0481000B1 (de)
JP (1) JP3039802B2 (de)
KR (1) KR100235266B1 (de)
AT (1) ATE179862T1 (de)
AU (1) AU638734B2 (de)
CA (1) CA2063431C (de)
DE (1) DE69033109T2 (de)
DK (1) DK0481000T3 (de)
ES (1) ES2133271T3 (de)
FI (1) FI920027A0 (de)
HU (1) HU215581B (de)
NO (1) NO310032B1 (de)
SG (1) SG72657A1 (de)
WO (1) WO1991000916A2 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9001466D0 (en) * 1990-01-23 1990-03-21 Erba Carlo Spa Extracellular form of the human fibroblast growth factor receptor
WO1991000916A2 (en) 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
JP2552942B2 (ja) * 1990-06-01 1996-11-13 三井東圧化学株式会社 ヒトｂーＦＧＦ受容体遺伝子
DE69133281T2 (de) * 1990-07-06 2004-05-06 Gencell S.A. Rezeptoren der wachstumsfaktoren aus fibroblasten
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
IL100219A0 (en) * 1991-12-02 1992-09-06 Yeda Res & Dev Variable region within fibroblast growth factor receptors that confers ligand specificity
ES2091018T3 (es) * 1992-06-18 1996-10-16 Whittier Inst Diabetes & Endoc Procedimiento para la deteccion de enfermedades neoplasicas.
ATE348110T1 (de) * 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6214795B1 (en) 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
AU3170499A (en) * 1998-04-28 1999-11-16 Eisai Co. Ltd. Fibroblast growth factor mutein compositions and methods of use therefor
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US20020192719A1 (en) * 1998-09-30 2002-12-19 Caliper Technologies Corp. Homogeneous assay methods
AU3224700A (en) * 1999-02-08 2000-08-25 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
IL146480A0 (en) * 1999-05-14 2002-07-25 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
JP2004527456A (ja) * 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
JP4262979B2 (ja) * 2000-11-21 2009-05-13 ザ・テキサス・エイ・アンド・エム・ユニバーシテイ・システム Ｆｇｆアフィニティークロマトグラフィー
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
WO2002102854A2 (en) * 2001-06-20 2002-12-27 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2003072126A2 (de) * 2002-02-28 2003-09-04 Switch Biotech Ag Verwendung eines fibroblastenwachstumsfaktor-bindeproteins zur behandlung und diagnose von diabetischen wundheilungsstörungen
EP1340507B1 (de) * 2002-02-28 2004-09-22 Switch Biotech Aktiengesellschaft Verwendung eines Fibroblastenwachstumsfaktor-Bindeproteins zur Behandlung und Diagnose von diabetischen Wundheilugnsstörungen
US20060281130A1 (en) 2002-12-20 2006-12-14 Elisabeth Bock Metod of modulation of interaction between receptor and ligand
EP1622941A2 (de) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Methode zur produktion von anti-egfr antikörpern
WO2005066211A2 (en) * 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
JP4734319B2 (ja) * 2004-03-19 2011-07-27 イムクローン・リミテッド・ライアビリティ・カンパニー ヒト抗上皮成長因子受容体抗体
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
WO2007014123A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
BRPI0719597A2 (pt) 2006-11-22 2013-12-17 Adnexus A Bristol Myers Squibb R & D Company Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
WO2009102421A2 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
EP2318529B1 (de) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Muteine in der sauren region der extrazellulären domäne von fgfr
US9279013B2 (en) 2008-10-10 2016-03-08 Amgen Inc. FGF-21 mutants comprising polyethylene glycol and uses thereof
MX2011000455A (es) 2008-11-07 2011-02-25 Galaxy Biotech Llc Anticuerpos monoclonales especificos al receptor 2 del factor de crecimiento de fibroblastos.
ES2932874T3 (es) * 2009-03-25 2023-01-27 Genentech Inc Anticuerpos anti-FGFR3 y métodos que utilizan los mismos
CN107188950B (zh) 2009-05-05 2021-09-28 安姆根有限公司 Fgf21突变体及其用途
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
CA2764835A1 (en) * 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
ES2600631T3 (es) 2009-11-13 2017-02-10 Five Prime Therapeutics, Inc. Uso de proteínas del dominio extracelular de FGFR1 para tratar cánceres caracterizados por mutaciones activadoras dependientes de ligando en FGFR2
US8372952B2 (en) * 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US8685931B2 (en) 2009-12-17 2014-04-01 Five Prime Therapeutics, Inc. Hair growth methods using FGFR3 extracellular domains
EP2558497A2 (de) 2010-04-15 2013-02-20 Amgen Inc. Menschlicher fgf-rezeptor und beta-klotho-bindeproteine
US8435525B1 (en) 2010-04-16 2013-05-07 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
US9226960B2 (en) 2010-04-16 2016-01-05 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
EP2569012A4 (de) 2010-05-11 2013-10-30 Aveo Pharmaceuticals Inc Anti-fgfr2-antikörper
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
AU2011329127B2 (en) 2010-11-15 2015-09-03 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
CA2855818A1 (en) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. A method of treating lung cancer having an fgfr1 gene amplification or fgfr1 overexpression
NZ715201A (en) 2013-08-01 2021-12-24 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
US10373702B2 (en) * 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
CA2999711A1 (en) 2014-09-26 2016-03-31 Rajendra Sahai Bhatnagar Inhibitors of nf kappa-b activity for treatment of diseases and disorders
WO2016197018A1 (en) 2015-06-05 2016-12-08 Ibio, Inc. Endostatin fragments and variants for use in treating fibrosis
BR112018010410A8 (pt) 2015-11-23 2019-02-26 Five Prime Therapeutics Inc método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1
BR112019023898A2 (pt) 2017-05-16 2020-06-09 Five Prime Therapeutics Inc método para tratamento de câncer gástrico, uso de um anticorpo e composição
AR123306A1 (es) 2020-08-21 2022-11-16 Genzyme Corp Anticuerpos fgfr3 y métodos de uso

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4785079A (en) * 1984-11-09 1988-11-15 The Salk Institute For Biological Studies Isolation of fibroblast growth factor
US4668476A (en) * 1984-03-23 1987-05-26 Applied Biosystems, Inc. Automated polypeptide synthesis apparatus
US4761371A (en) 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5057417A (en) * 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US5081228A (en) * 1988-02-25 1992-01-14 Immunex Corporation Interleukin-1 receptors
US4968607A (en) * 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
SE8804164A0 (sv) * 1988-11-17 1990-05-18 Per Prisell Farmaceutisk beredning
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
WO1991000916A2 (en) * 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
US5229501A (en) * 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
US6022741A (en) * 1997-03-13 2000-02-08 University Of North Carolina At Chapel Hill Regulatory genetic DNA that regulates the Class II transactivator (CIITA)

Also Published As

Publication number Publication date
WO1991000916A3 (en) 1991-10-17
KR100235266B1 (en) 1999-12-15
NO920060L (no) 1992-03-02
HU906195D0 (en) 1992-06-29
AU6077990A (en) 1991-02-06
SG72657A1 (en) 2000-05-23
NO920060D0 (no) 1992-01-03
DK0481000T3 (da) 1999-11-15
FI920027A0 (fi) 1992-01-03
US6384191B1 (en) 2002-05-07
AU638734B2 (en) 1993-07-08
HUT61052A (en) 1992-11-30
US5707632A (en) 1998-01-13
ATE179862T1 (de) 1999-05-15
US6355440B1 (en) 2002-03-12
EP0481000A4 (en) 1992-10-21
CA2063431C (en) 2002-10-29
WO1991000916A2 (en) 1991-01-24
JPH04506604A (ja) 1992-11-19
JP3039802B2 (ja) 2000-05-08
EP0481000A1 (de) 1992-04-22
DE69033109T2 (de) 1999-11-18
ES2133271T3 (es) 1999-09-16
NO310032B1 (no) 2001-05-07
EP0481000B1 (de) 1999-05-12
US6350593B1 (en) 2002-02-26
CA2063431A1 (en) 1991-01-07
HU215581B (hu) 1999-01-28

Similar Documents

Publication Publication Date Title
DE69033109T2 (de) Rezeptoren für fibroblasten-wachstumsfaktoren
D'Andrea et al. Expression cloning of the murine erythropoietin receptor
Gearing et al. Expression cloning of a receptor for human granulocyte‐macrophage colony‐stimulating factor.
EP0555989B1 (de) TGF-Beta induziertes Gen und Protein
Moreau et al. Leukaemia inhibitory factor is identical to the myeloid growth factor human interleukin for DA cells
Kondo et al. Expression of functional human interleukin-2 receptor in mouse T cells by cDNA transfection
CA2076979C (en) Substantially pure transforming growth factor-.beta.-1-binding protein and nucleotide sequences expressing the binding protein
Barry et al. Two contiguous residues in human interleukin-3, Asp21 and Glu22, selectively interact with the alpha-and beta-chains of its receptor and participate in function.
DE69638022D1 (de) Aus wirbeltieren und darauf basierende verfahren
DK0861261T3 (da) Nukleotid- og proteinsekvenser af hvirveldyrs-Delta-gener og fremgangsmåder baseret derpå
EP1073740A1 (de) Aus hautzellen isolierte polynukleotide und verfahren für ihre verwendung.
BartňÏk et al. Avian stem cell factor (SCF): production and characterization of the recombinant His-tagged SCF of chicken and its neutralizing antibody
AU637133B2 (en) Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
WO2000069884A2 (en) Compositions isolated from skin cells and methods for their use
ES2134771T5 (es) Adn que codifica el receptor del factor estimulador de una colonia de granulocitos.
Fabisiak et al. Platelet-derived growth factor
Too et al. Prolactin induces expression of FGF-2 and a novel FGF-responsive NonO/p54nrb-related mRNA in rat lymphoma cells
Axelrod et al. The interferon-gamma receptor extracellular domain. Non-identical requirements for ligand binding and signaling.
EP0490410B1 (de) TXA2-Rezeptor und dafür kodierendes Gen
Minamoto et al. Ligand-dependent selection of the receptor gene: segregation of IL-2 binding activity and anti-Tac reactivity by a single amino acid alteration in the Tac antigen (p55)
Zhang et al. Amino acids 67 and 68 of transforming growth factor-β regulate binding to a glycosyl phosphatidyl inositol-linked membrane protein on vascular endothelial cells
AU699824B2 (en) DNA sequence coding for a BMP receptor
Betsholtz et al. Platelet-derived growth factor—Structural and functional aspects of the A-chain gene
Kimberley et al. The HSPG binding domain of APRIL serves as a platform for ligand multimersation and cross-linking.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition